Trofinetide in young girls: what does DAFFODIL show?
An open-label study in 15 girls aged 2–4.
Med · PMID 40043705
Dated overview
Concrete information, sources you can open.
How this data was assembledFOR FAMILIES AND THEIR LOVED ONES
Research moves forward.Let’s understand it, together.
Where does Rett syndrome research stand? Clear guidance to follow research, explore trials and understand each advance.
Plain languageAccessible sourcesAt your own pace
START HERE
You don’t have to be a scientist.
A discovery, a trial and an available treatment are different things. Let’s make sense of them.
In the laboratory
In people
Treatment access
RE2TAt your own pace
Some summaries and translations are AI-assisted. They may contain errors, are being reviewed progressively, and never replace medical advice.
RE2T research catalogue connectedPublished RE2T catalogue
Concrete information, sources you can open.
6documented studies
3papers explained
5reading languages
Dated overview
Where do things stand today?
A dated summary, sourced recent changes, then clear paths to understand approaches, trials, papers and support.
Recent changes
- Trofinetide · LAVENDERSep 8, 2026
- Trofinetide · DAFFODILSep 8, 2026
- Fenfluramine · Phase 3Aug 17, 2026
No new qualified news published today
The watch publishes nothing when no relevant change has been qualified. This empty state is intentional and does not mean a failure.
Approaches explored
Understand what researchers are trying to change.
Trials to understand
Explore studies by country, age and recruitment.
Understand the steps
From the laboratory to everyday life: understand the journey.
Support usefully
Understand. Share reliable information. Support a research project. There is a place for everyone.
RE2T
Quick entry by profile
Choose the entry point that matches your question today.
01
New diagnosis
Understand the steps without confusing discovery, trial and available treatment.
02
France
Find sources, French centres when listed, and the limits of this selection.
03
Professional
Open primary sources, dates, criteria and caveats before any clinical discussion.
04
Press / partner
Check RE2T’s role, sources and absence of medical promise before quoting.
Overview
What would you like to know?
Three ways in. No jargon, no need to read everything.
Reading room
Research papers, explained simply.
Three selected papers: their observations, limitations and original sources.
LAVENDER: reading results alongside tolerability.
A 12-week comparative trial, published in 2023.
Nature Medicine · PMID 37291210
LAVENDER protocol: how the phase 3 trial was designed
The protocol and outcome measures for a 12-week study in 187 participants aged 5 to 20.
Contemporary Clinical Trials · PMID 35149233
RE2T · Support research
Moving research forward is a shared story.
Understand. Share reliable information. Support a research project. There is a place for everyone.